Journal
EMBO MOLECULAR MEDICINE
Volume 6, Issue 9, Pages 1205-1214Publisher
WILEY-BLACKWELL
DOI: 10.15252/emmm.201404075
Keywords
cystic fibrosis; long chain base; lung infection; Pseudomonas aeruginosa; sphingosine
Categories
Funding
- German-Israeli-Foundation [1105-69.11/2010]
- DFG grant [335/16-2]
- BMBF-grant [0315827B]
- NIH grant [DK25809]
Ask authors/readers for more resources
Cystic fibrosis patients and patients with chronic obstructive pulmonary disease, trauma, burn wound, or patients requiring ventilation are susceptible to severe pulmonary infection by Pseudomonas aeruginosa. Physiological innate defense mechanisms against this pathogen, and their alterations in lung diseases, are for the most part unknown. We now demonstrate a role for the sphingoid long chain base, sphingosine, in determining susceptibility to lung infection by P.aeruginosa. Tracheal and bronchial sphingosine levels were significantly reduced in tissues from cystic fibrosis patients and from cystic fibrosis mouse models due to reduced activity of acid ceramidase, which generates sphingosine from ceramide. Inhalation of mice with sphingosine, with a sphingosine analog, FTY720, or with acid ceramidase rescued susceptible mice from infection. Our data suggest that luminal sphingosine in tracheal and bronchial epithelial cells prevents pulmonary P.aeruginosa infection in normal individuals, paving the way for novel therapeutic paradigms based on inhalation of acid ceramidase or of sphingoid long chain bases in lung infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available